Phase II feasibility study of adjuvant S-1 plus docetaxel repeated for 6 months as adjuvant chemotherapy for Stage III gastric cancer after curative D2 gastrectomy (OGSG 1002)

Kimura, K. Fujitani, S. Tamura, J. Matsuyama, H. Imamura, J. Fujita, S. Iijima, S. Ueda, T. Shimokawa, Y. Kurokawa, T. Satoh, T. Tsujinaka, H. Furukawa ESMO-GI 2014, Barcelona, Spain,25-28 Jun 2014